Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Identification of a preneoplastic gene expression profile in tubal epithelium of BRCA1 mutation carriers.

Press JZ, Wurz K, Norquist BM, Lee MK, Pennil C, Garcia R, Welcsh P, Goff BA, Swisher EM.

Neoplasia. 2010 Dec;12(12):993-1002.

2.

Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers.

George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, Virtanen C, Shaw PA.

J Pathol. 2011 Sep;225(1):106-17. doi: 10.1002/path.2927. Epub 2011 Jul 8.

PMID:
21744340
3.

E2F3b over-expression in ovarian carcinomas and in BRCA1 haploinsufficient fallopian tube epithelium.

Smith NL, Welcsh P, Press JZ, Agnew KJ, Garcia R, Swisher EM.

Genes Chromosomes Cancer. 2012 Nov;51(11):1054-62. doi: 10.1002/gcc.21990. Epub 2012 Aug 9.

PMID:
22887716
4.

Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.

Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA.

Clin Cancer Res. 2008 Jul 1;14(13):4067-78. doi: 10.1158/1078-0432.CCR-07-4959.

5.

Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.

Staff S, Tolonen T, Laasanen SL, Mecklin JP, Isola J, Mäenpää J.

Int J Gynecol Pathol. 2014 May;33(3):309-16. doi: 10.1097/PGP.0b013e31829c673b.

PMID:
24681744
6.

Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.

George SH, Milea A, Shaw PA.

Clin Cancer Res. 2012 Nov 15;18(22):6199-207. doi: 10.1158/1078-0432.CCR-12-2155. Epub 2012 Sep 11.

7.

Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.

Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B.

Int J Gynecol Pathol. 2004 Jan;23(1):35-40.

PMID:
14668548
8.

The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations.

Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM.

Cancer. 2010 Nov 15;116(22):5261-71. doi: 10.1002/cncr.25439.

9.

Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers.

Bijron JG, van der Groep P, van Dorst EB, Seeber LM, Sie-Go DM, Verheijen RH, van Diest PJ.

Endocr Relat Cancer. 2012 Feb 13;19(1):69-81. doi: 10.1530/ERC-11-0338. Print 2012 Feb.

10.

A candidate precursor to serous carcinoma that originates in the distal fallopian tube.

Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, Cramer DW, McKeon FD, Crum CP.

J Pathol. 2007 Jan;211(1):26-35. Erratum in: J Pathol. 2007 Sep;213(1):116.

PMID:
17117391
11.

Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations.

Rabban JT, Crawford B, Chen LM, Powell CB, Zaloudek CJ.

Am J Surg Pathol. 2009 Jan;33(1):111-9. doi: 10.1097/PAS.0b013e31817d74a7.

PMID:
18830124
12.

Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.

Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.

Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.

PMID:
22710074
13.

Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.

Vicus D, Shaw PA, Finch A, Rosen B, Murphy J, Armel S, Sun P, Narod SA.

Gynecol Oncol. 2010 Sep;118(3):295-8.

PMID:
20722102
14.

Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers.

Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H.

Mod Pathol. 2009 Sep;22(9):1133-8. doi: 10.1038/modpathol.2009.89. Epub 2009 Jun 19.

15.

[Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].

Wen J, Shi JL, Shen DH, Chen YX, Song QJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Jul;41(7):433-7. doi: 10.3760/cma.j.issn.0529-5807.2012.07.001. Chinese.

PMID:
22932451
16.

Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.

Piek JM, Torrenga B, Hermsen B, Verheijen RH, Zweemer RP, Gille JJ, Kenemans P, van Diest PJ, Menko FH.

Fam Cancer. 2003;2(2):73-8.

PMID:
14574155
17.

Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM.

Am J Obstet Gynecol. 2006 Jun;194(6):1702-9.

PMID:
16731090
18.

Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.

Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ.

Br J Cancer. 2004 Apr 19;90(8):1492-7.

19.

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH.

J Pathol. 2001 Nov;195(4):451-6.

PMID:
11745677
20.

A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.

Cass I, Walts AE, Barbuto D, Lester J, Karlan B.

Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.

PMID:
25026639
Items per page

Supplemental Content

Write to the Help Desk